Results 191 to 200 of about 26,548 (293)

Songorine inhibits mitophagy in chronic heart failure via the TBC1D15/Fis1/Rab7A pathway

British Journal of Pharmacology, Volume 183, Issue 9, Page 1939-1957, May 2026.
Abstract Background and purpose Songorine (SGR) is an alkaloid extracted from Aconitum carichaelii Debx. and has a demonstrated role in cardiac dysfunction. Chronic heart failure (CHF) is a severe clinical syndrome leading to functional impairment and death, primarily due to the deterioration of energy metabolism in cardiomyocytes. However, the precise
Wenxiu Liu, Xingju Zou, Yang Zheng, Chen Sun, Cheng Peng   +4 more
wiley   +1 more source

Implication of the Dose of Mineralocorticoid Receptor Antagonist Following Transcatheter Edge-to-Edge Mitral Valve Repair. [PDF]

JACC Asia
Imamura T, Tanaka S, Fukuda N, Ueno H, Kinugawa K, Kubo S, Yamamoto M, Izumi Y, Saji M, Asami M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Yamaguchi J, Naganuma T, Bota H, Ohno Y, Hachinohe D, Yamawaki M, Mizutani K, Otsuka T, Hayashida K, the, OCEAN-Mitral Investigators.   +27 more
europepmc   +1 more source

Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks. [PDF]

Clin J Am Soc Nephrol, 2022
Epstein M, Pecoits-Filho R, Clase CM, Sood MM, Kovesdy CP, Kovesdy CP.   +5 more
europepmc   +1 more source

Pharmacological inhibition of hydroxysteroid 11‐beta dehydrogenase type 1 (11‐βHSD1) after myocardial infarction preserves cardiac function in a translational mini‐pig model

British Journal of Pharmacology, Volume 183, Issue 10, Page 2236-2255, May 2026.
Abstract Background and Purpose Plasma glucocorticoids increase acutely after MI, thereafter tissue levels are amplified selectively within cells expressing 11‐ßhydroxysteroid dehydrogenase type 1 (11‐ßHSD1) that regenerates active glucocorticoids from circulating metabolites.
Sara Al Disi, Raimondo Ascione, Shazia Khan, Thomas Johnson, Eva Sammut, Vito Domenico Bruno, Daniel Baz Lopez, Carol‐Anne James, Joanna Simpson, Natalie Z. Homer, Michael Millar, Trisha Singh, Alex von Kreigsheim, Nick L. Mills, Brian R. Walker, Ruth Andrew, Scott P. Webster, Andrew Whittaker, Adrian Freeman, Gillian A. Gray   +19 more
wiley   +1 more source

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone. [PDF]

Circ Rep, 2021
Oshima A, Imamura T, Narang N, Kinugawa K.   +3 more
europepmc   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3974-3984, May 2026.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS). [PDF]

Pragmat Obs Res
Richard EL, Stephenson JJ, Desai NR, Willey VJ, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng CC, Oberprieler NG.   +10 more
europepmc   +1 more source

Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy. [PDF]

Ther Adv Chronic Dis, 2023
Liao CW, Lin YT, Tsai CH, Chang YY, Chen ZW, Lu CC, Pan CT, Chang CC, Lee BC, Chiu YW, Huang WC, Huang KH, Lai TS, Hung CS, Wu VC, Wu XM, Lin YH, TAIPAI Study Group.   +17 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3568-3581, May 2026.
Abstract The mineralocorticoid receptor (MR) has a multifaceted role in normal physiologic functions. However, research has uncovered the deleterious consequences of overactivation of the MR. It has been implicated in chronic kidney disease (CKD) via its strong association with glomerulosclerosis, interstitial fibrosis, proteinuria, and decline in ...
Amy K. Mottl, Kamlesh Khunti, Chantal Mathieu   +2 more
wiley   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease. [PDF]

Kidney Dis (Basel), 2023
Liu W, Yu S.
europepmc   +1 more source